Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. Mikkael Sekeres is the Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute. He has been Medical Advisory Board Co-Chair since 2004. Dr. Sekeres is also Vice Chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute in Ohio. He earned his medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. Dr. Sekeres completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston. He also chaired the Oncologic Drugs Advisory Committee of the FDA.
An invited speaker at numerous meetings, grand rounds and conferences, Dr. Sekeres is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the Southwest Oncology Group—Leukemia Committee. His current research focuses on patients with MDS and older adults with acute myeloid leukemia, and he has been the national primary study investigator on several phase I/II trials. He is the author or co-author of over 230 articles and over 250 abstracts published in leading journals such as Blood, Journal of Clinical Oncology, Nature Genetics, Journal of the National Cancer Institute, PLoS One, Cancer, Haematologica and Leukemia. He is also the co-author of six books; the editor-in-chief of the ASH Clinical News magazine; he is on the editorial board of several journals; and is an essayist for The New York Times and Huffington Post.